Skip to Main Content
Open, not recruiting

SJATRT: Phase II Study of Alisertib Therapy for Rhabdoid Tumors

About this study

SJATRT is a clinical trial studying more effective treaatments for a rare and fast-growing cancerous tumor called malignant rhabdoid tumor (MRT). MRTs are types of tumors that are found in the brain, and/or in other areas of the body, particularly the kidneys, but also liver and other soft tissue sites. When an MRT originates in the brain or spinal cord, it is usually called an atypical teratoid rhabdoid tumor (ATRT).

MRTs and ATRTs can be difficult to cure. Children with MRTs and ATRTs are usually treated with surgery, radiation therapy and chemotherapy drugs.

Treatment on this research study is based on a “risk-adapted” approach. Children taking part in this study will be divided into different risk groups. The risk group your child will be assigned to depends on certain aspects of your child’s tumor, such as age at diagnosis and whether or not the tumor has spread to the spinal fluid and/or other areas of the brain and spine.


There are three parts to this study:

  • Staging–The first step is to determine how much tumor is present and where it has spread.
  • Treatment – Treatment depends on several key factors, including if the tumor is recurrent/progressive or newly diagnosed, your child’s age and clinical risk. All participants enrolled in this study will be treated with alisertib. Some participants may also receive treatment with surgery, chemotherapy and radiation.
  • Follow-up – After treatment ends, routine follow-up examinations and medical tests will be done for about five years following treatment.

Eligibility overview

  • Has one of the following:
    • Newly diagnosed atypical teratoid rhabdoid tumors (ATRTs) with or without tumors affecting other areas outside the brain and spine
    • ATRTs or malignant rhabdoid tumors (MRTs) that have come back after initial treatment (recurrent/progressive disease)
  • 21 years of age or younger

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.


Full title:

Phase II Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (ATRT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed ATRT

Study goal:

The main purpose of SJATRT is to study the effects of an experimental study drug called alisertib in children and young adults with recurrent or progressive ATRTs or MRTs, and those with newly diagnosed ATRT.


Brain tumorsolid tumor


21 years old or younger

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.


Learn more